07:00 , Sep 29, 2003 |  BC Extra  |  Financial News

SPPI raises $20 million

Spectrum Pharmaceuticals (SPPI) raised $20 million in a private placement of convertible preferred stock and warrants. Investors included Baystar Capital; SDS Merchant Fund; SCO Capital Partners; Xmark Funds; Quogue Capital; and ProMed Partners. SCO Securities...
07:00 , Jul 16, 2003 |  BC Extra  |  Financial News

Genetronics raises $15.7 million

Genetronics (GEB; TSE:GEB) raised $15.7 million in a private placement of series A and B convertible notes. The notes convert into GEB shares at $0.60 and $0.70, respectively, and bear 6% interest. Each shareholder also...
07:00 , Jun 20, 2003 |  BC Extra  |  Financial News

Discovery Labs raises $27.5 million

Pulmonary company DSCO raised $27.5 million in a private placement of 5 million shares at $5.50. Investors included Quaker BioVentures; BayStar Capital; Special Situations Funds; PharmaBio Development; and Laboratorios Del Dr. Esteve . Gerard Klauer...
07:00 , Jun 13, 2003 |  BC Extra  |  Financial News

Dendreon raises $26.7 million

Cancer company DNDN raised $26.7 million in a private placement of 3.8 million shares at $7. Investors included Baystar Capital; Mazama Capital Management; and another existing DNDN stockholder. The company said it will use the...
07:00 , May 28, 2003 |  BC Extra  |  Financial News

Vivus raises $17.5 million

Sexual dysfunction company VVUS raised $17.5 million in a private placement of 4.4 million shares at $4. Investors included Zesiger Capital; SAC Capital; Royal Bank of Canada; Special Situations Funds; and Baystar Capital II. C.E....
07:00 , May 12, 2003 |  BioCentury  |  Finance

Ebb & Flow

For the past few years, the major focus for investors in Neurobiological Technologies (NTII) has been on its Memantine , which is marketed in Europe for Alzheimer's disease and is awaiting U.S. approval for the...
08:00 , Apr 2, 2003 |  BC Extra  |  Financial News

Orchid raises $16 million

Genetic profiling company ORCH raised $16 million through the sale of 1,600 shares of convertible preferred stock at $10,000 to BayStar Capital; SDS Capital Partners; and other investors. Each preferred share converts into 22,222 shares...
07:00 , Oct 23, 2000 |  BioCentury  |  Finance

Mutual respect for biotech

Although biotech stocks have taken a drubbing so far this quarter, fund managers do not appear to be getting out of the group or increasing the percentage of cash holdings in their funds. Nor does...
07:00 , Oct 16, 2000 |  BC Extra  |  Financial News

Cellomics raises $30 million

Cell-based drug discovery company Cellomics (Pittsburgh, Penn.) raised $30 million in a private round. Investors included Amerindo Investment Advisors; INVESCO; Alta Partners; Burrill Biotechnology Capital Fund; BayStar Capital; Ariane Health Fund; LCF Rothschild; Biosphere; InterWest...
07:00 , Oct 9, 2000 |  BioCentury  |  Emerging Company Profile

Camitro: Predicting ADMET

Camitro Corp.'s goal is to overcome one of the major bottlenecks in drug discovery: identifying compounds with acceptable properties of absorption, distribution, metabolism, excretion and toxicity (ADMET). Indeed, getting compounds with appropriate ADMET properties requires...